Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
NeOnc Technologies announced that CEO Amir Heshmatpour purchased 80,000 shares of common stock in the open market, bringing his total 2026 personal investment to 271,000 shares. Additionally, the company received a Type B End-of-Phase meeting from the FDA scheduled for January 2027 to discuss an accelerated approval pathway for its brain cancer candidate, NEO100.
Beyond Air reported record quarterly revenue of $2.3 million for the period ended September 30, 2026, representing 28% year-over-year growth. The company reaffirmed its revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 while awaiting FDA approval for its second-generation LungFit PH system.
Term
Q2 2027
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system.”
Robert Goodman, Chief Executive Officer of Beyond Air
Co-Diagnostics held a court-ordered special meeting of shareholders on November 13, 2026, where shareholders elected five directors and approved an amendment to the 2025 Equity Incentive Plan. The amendment increases the number of shares authorized for issuance under the plan by 2,000,000 shares, bringing the total maximum to 2,223,333 shares. Shareholders also approved a non-binding advisory resolution regarding executive compensation.
Q/C Technologies received a deficiency notice from Nasdaq on November 6, 2026, because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, or until May 5, 2027, to regain compliance with the minimum bid price requirement. If compliance is not regained, the company may be eligible for an additional 180-day period or face delisting.
NextBoat $823K Debt Financing with Hadley Harbor Group LLC
NextBoat Inc.'s subsidiary, Off The Hook Yacht Sales NC, LLC, entered into a seven-year triple-net lease for 22 boat slips at Cape Fear Marina with Hadley Harbor Group LLC. The company provided a corporate guaranty for the lease obligations, which total approximately $0.82 million in base rent over the term. The transaction is a related-party deal involving the company's Chairman and a Director.
Delta Air Lines EVP - Global Sales & Distrib Steven M. Sear Sells $1.58M of Stock
Steven M. Sear, EVP - Global Sales & Distrib, sold 17,768 shares of Delta Air Lines, Inc. at $88.95 a share, worth $1.58M in total on Nov 12, 2026. Shares held after the trade: 86,636 (-17.0%).
Spruce Power Holding Corp reported 19,294,133 shares of common stock outstanding as of November 9, 2026. The company's cash and cash equivalents decreased from $54.8 million at the end of 2025 to $40.1 million as of September 30, 2026, while management highlighted risks related to debt refinancing and solar industry demand.
BRC Group Holdings, Inc. announced it is eliminating the role of Chief Accounting Officer effective November 16, 2026. As a result, Howard Weitzman will step down from the position but will remain with the company as Head of Corporate Tax, transitioning out of his status as an executive officer.
Evofem Biosciences reported Q3 2026 financial results, achieving $0.7 million in operating income despite a slight decline in net sales to $4.6 million. The company highlighted the shipment of its 500,000th box of PHEXX and the addition of a fifth study site for an NIH-funded Phase 4 trial of SOLOSEC.
Term
Q3 2026
“While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products.”
byNordic Acquisition Corp deposited $8,850.20 into its trust account to extend the deadline for completing its initial business combination by one month. The extension moves the termination date from November 12, 2026, to December 12, 2026, and represents the fourth of twelve possible monthly extensions.
BioScience Health Innovations, Inc. reported a net loss of $564,885 for the nine months ended September 30, 2026, a significant decline from the $875,720 net income in the prior year period. Despite the loss, the company successfully raised over $2 million through common stock sales, ending the period with a strengthened cash position of $1,691,858.
KKR Private Equity Conglomerate LLC reported a net increase in net assets resulting from operations of $975.5 million for the nine months ended September 30, 2026, compared to $762.1 million in the prior year period. Total assets grew to $13.6 billion, driven by a significant increase in investments at fair value and cash holdings.
Evofem Biosciences reported a significant decline in total assets from $20.3 million at year-end 2025 to $7.3 million as of September 30, 2026, driven largely by a decrease in trade accounts receivable and intangible assets. The company faces substantial liquidity challenges with $84.8 million in current liabilities and has received notices of default from Future Pak, LLC regarding its debt obligations.
Senior Credit Investments, LLC reported a net increase in member’s capital resulting from operations of $18.4 million for the nine months ended September 30, 2026, up from $12.0 million in the prior year period. Total investment income grew significantly to $40.4 million, driven by interest income from its non-controlled/non-affiliated investment portfolio, while net asset value per unit decreased slightly to $1,767.94 from $1,787.98 at year-end 2025.
Jefferies Credit Partners BDC Inc. reported a net increase in net assets resulting from operations of $52.0 million for the nine months ended September 30, 2026, compared to $30.5 million for the same period in 2025. Total net assets grew to $964.9 million from $677.0 million at year-end 2025, driven by significant capital share issuances and investment income growth.
The 21Shares Solana Staking ETF reported net assets of $9,786,070 as of September 30, 2026, a significant increase from $5,735,019 at the end of 2025. The Trust generated $102,143 in staking rewards for the nine months ended September 30, 2026, and transitioned its pricing benchmark to the FTSE Solana Index in August 2026.
Mirum Pharmaceuticals Director Laura Brege Sells $1.33M of Stock
Laura Brege, Director, sold 14,167 shares of Mirum Pharmaceuticals, Inc. at $94.05 to $94.74 a share (average $94.21) in 2 transactions, worth $1.33M in total on Nov 11, 2026. Shares held after the trade: 15,703 (-17.2%).
Vital Farms 10% Owner Matthew Ohayer Sells $222K of Stock
Matthew Ohayer, 10% Owner, sold 23,250 shares of Vital Farms, Inc. at $9.56 a share, worth $222K in total on Nov 11, 2026. Shares held after the trade: 6,238,720 (-0.4%).
Blue Line Holdings, Inc. remains a pre-revenue industrial company with a net loss of $12,459 for the quarter ended September 30, 2026. The company reported a working capital deficit of $90,521 and expressed substantial doubt regarding its ability to continue as a going concern without additional financing.
INNOVATE Corp. filed a prospectus supplement to establish a new $50 million at-the-market (ATM) equity offering program through Jefferies LLC. This program replaces a previous registration statement that expired in October 2026 and increases the potential offering amount from $31 million to $50 million. The filing also includes pro forma financial data reflecting the company's recent divestitures of its Broadcasting and DBM Global business units.
For the quarter ended September 30, 2026, INVE Technologies reported a net income of $0.6 million, a significant improvement from a $3.5 million loss in the prior year, primarily driven by a $6.1 million gain on an asset sale. However, total revenue decreased to $3.1 million from $5.0 million year-over-year, and the company recorded a nine-month net loss of $7.5 million.
Femasys Inc. reported a decrease in sales for the nine months ended September 30, 2026, totaling $1,161,313 compared to $1,479,926 in the prior year period. The company significantly strengthened its balance sheet, ending the quarter with $23.9 million in cash and cash equivalents following financing activities, while maintaining an accumulated deficit of $154 million.
Edgemode, Inc. reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a loss of $14.4 million in the prior year period. The company's balance sheet shows a significant stockholders' deficit of $7.6 million and a substantial reduction in derivative liabilities from $15.4 million to $1.5 million during the year.
American Strategic Investment Co. reported a net loss of $22.8 million for the nine months ended September 30, 2026, compared to a $14.5 million loss in the prior year. The company's total equity decreased to $47.3 million from $64.8 million at year-end 2025, primarily driven by the net loss and offset by common stock issuances to its Advisor.
10x Genomics CEO Serge Saxonov Sells $1.95M of Stock
Serge Saxonov, CEO, sold 31,000 shares of 10x Genomics, Inc. at $62.90 a share, worth $1.95M in total on Nov 10, 2026. Shares held after the trade: 1,019,249 (-3.0%).
Santander Holdings USA, Inc. is recasting its historical financial statements for 2023, 2024, and 2025 to reflect changes in its internal management reporting structure. The company combined its Commercial & Industrial and Commercial Real Estate segments into a single Commercial Banking segment, and this filing provides the recast segment data for informational purposes without restating overall consolidated results.
This document is a formal consent from Altus Group U.S., Inc. allowing Hines Global Income Trust, Inc. to reference their role as an independent valuer in the company's Q3 2026 Quarterly Report. It specifically pertains to the valuation process described in the Net Asset Value section of the filing.
Origin Investment Corp I reported a net income of $1,165,890 for the nine months ended September 30, 2026, primarily driven by $1,937,643 in interest income from its Trust Account. As a blank check company, it has not yet commenced operations or generated revenue, and its total assets of $73.36 million are largely comprised of investments held in trust for a future business combination.
Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.
Term
Q3 2026
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”
Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
CKX Lands, Inc. reported net income of $621,499 for the nine months ended September 30, 2026, an increase from $442,919 in the prior year period, driven largely by higher surface revenue and interest income. Total assets remained stable at approximately $22.4 million, while the company maintained a strong liquidity position with $15.9 million in cash and cash equivalents.